Vol 71, No 3 (2020)
Clinical vignette
Published online: 2020-06-03

open access

Page views 1013
Article views/downloads 781
Get Citation

Connect on Social Media

Connect on Social Media

Parathyroid imaging with [99mTc]Tc-MIBI SPECT/CT — unexpected findings of bone marrow involvement of non-Hodgkin’s lymphoma

Jolanta Kunikowska1, Leszek Królicki1
Pubmed: 33140382
Endokrynol Pol 2020;71(3):271-272.


Not required for Clinical Vignette.

Article available in PDF format

View PDF Download PDF file


  1. Ohta M, Isobe K, Kuyama J, et al. Clinical role of Tc-99m-MIBI scintigraphy in non-Hodgkin's lymphoma. Oncol Rep. 2001; 8(4): 841–845.
  2. Fujii H, Nakamura K, Kubo A, et al. 99mTc-MIBI scintigraphy as an indicator of the chemosensitivity of anthracyclines in patients with breast cancer. Anticancer Res. 1998; 18(6B): 4601–4605.
  3. Lazarowski A, Dupont J, Fernández J, et al. 99mTechnetium-SESTAMIBI uptake in malignant lymphomas. Correlation with chemotherapy response. Lymphat Res Biol. 2006; 4(1): 23–28.
  4. Fonti R, Del Vecchio S, Zannetti A, et al. Bone marrow uptake of 99mTc-MIBI in patients with multiple myeloma. Eur J Nucl Med. 2001; 28(2): 214–220.
  5. Fonti R, Pace L, Cerchione C, et al. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in the prediction of outcome of patients with multiple myeloma: a comparative study. Clin Nucl Med. 2015; 40(4): 303–308.